EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations

Zubaida Bibi, Kausar Ali

European Journal of Clinical Pharmacology · 2026-07 · 82 (7)

DOI: 10.1007/s00228-026-04125-4 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 23.06.2026. Verfasst von Zubaida Bibi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ayub Medical College, Abbottabad, Pakistan. drzubaida241@gmail.com. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Ayub Medical College, Abbottabad, Pakistan. drzubaida241@gmail.com.
  • KUST, Kohat, Pakistan.

Zitieren

APA

Bibi, Z., & Ali, K. (2026). Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04125-4

Vancouver

Bibi Z, Ali K. Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04125-4

BibTeX
@article{Bibi2026,
  author = {Bibi, Zubaida and Ali, Kausar},
  title = {Interpreting neutral findings in CA-AKI prevention trials: additional methodological considerations},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {7},
  doi = {10.1007/s00228-026-04125-4}
}
Kostenlos starten →